Germline <i>RET</i> variants underlie a subset of paediatric osteosarcoma.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 32179705.
- Also identified by DOI 10.1136/jmedgenet-2019-106734.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Although considerable effort has been put into decoding of the osteosarcoma genome, very little is known about germline mutations that underlie this primary malignant tumour of bone. We followed here a coincidental finding in a multiple endocrine neoplasia family in which a 32-year-old patient carrying a germline pathogenic <i>RET</i> mutation developed an osteosarcoma 2 years after the resection of a medullary thyroid carcinoma. Sequencing analysis of additional 336 patients with osteosarcoma led to the identification of germline activating mutations in the <i>RET</i> proto-oncogene in three cases and somatic amplifications of the gene locus in five matched tumours (4%, n=5/124 tumours). Functional analysis of the pathogenic variants together with an integrative analysis of osteosarcoma genomes confirmed that the mutant RET proteins couple functional kinase activity to dysfunctional ligand binding. <i>RET</i> mutations further co-operated with alterations in <i>TP53</i> and <i>RB1</i>, suggesting that osteosarcoma pathogenesis bears reminiscence to the stepwise model of medullary thyroid carcinoma. After Li-Fraumeni-predisposing mutations in <i>TP53</i>, <i>RET</i> becomes the second most mutated cancer-predisposing gene in the germline of patients with osteosarcoma. Hence, early identification of <i>RET</i> mutation carriers can help to identify at-risk family members and carry out preventive measures.
Medical subject headings
- Carcinoma, Neuroendocrine
- Osteosarcoma
- Proto-Oncogene Proteins c-ret
- Retinoblastoma Binding Proteins
- Thyroid Neoplasms
- Tumor Suppressor Protein p53
- Ubiquitin-Protein Ligases